MitoCareX Bio Deploys Computational Drug Discovery Infrastructure on Google Cloud

On October 7, 2026, Nexentis Technologies Inc. announced that its drug discovery subsidiary had deployed its computational infrastructure on the Google Cloud Platform.¹ The subsidiary, MitoCareX Bio Ltd., is wholly owned by Nexentis and focuses on a drug-discovery platform.¹ This move involves MitoCareX's Computational Drug Discovery Infrastructure, which is central to its research.¹ Nexentis Technologies, the parent company, is publicly traded on the NASDAQ exchange under the ticker symbol NXTS.¹

The deployment is designed to improve computational power, oversight of data, and the flexibility of operations as MitoCareX moves its drug discovery programs forward.¹ This transition to the cloud is meant to establish a secure and adaptable computing environment for the company's research activities.¹ The new infrastructure is intended to accommodate the evolving needs of MitoCareX's drug discovery work.¹ A primary goal is to provide a resilient framework for the management of the company's computational research.¹

One expected outcome is that MitoCareX will be able to align its computing capacity directly with the needs of its various programs.¹ The Google Cloud Platform environment is expected to allow computing and storage resources to adjust as the requirements of projects change.¹ This adaptability is intended to support the company's existing research programs effectively.¹ Furthermore, the framework is expected to help the company assess new discovery opportunities when its research priorities shift.¹

The new cloud-based environment is anticipated to centralize the management of the company's scientific data.¹ It is also designed to implement a consistent system for user permissions that applies to both scientific and technical activities.¹ This structure is meant to support controlled access to scientific data that is shared among teams.¹ A key objective of the new environment is to reinforce the governance of data access and ensure the integrity of the data.¹

The infrastructure deployment is also expected to help create more efficient workflows within the organization.¹ Another stated goal is to encourage operational continuity across all of MitoCareX's research functions.¹ These capabilities are intended to furnish MitoCareX with a durable structure for overseeing its computational research efforts.¹ The continued enhancement of MitoCareX's scientific and technical abilities is an important component of Nexentis's corporate strategy.¹

David Palach, the Chief Executive Officer of Nexentis Technologies, stated that this transition is a significant move for the company.¹ He characterized the migration of MitoCareX's computational platform to a Google Cloud-based environment as an important step.¹ According to Palach, the change is intended to strengthen the operational foundation for the next stage of MitoCareX's development.¹ The deployment aims to give the company's scientific teams an adaptable environment that aligns with the changing needs of their discovery programs.¹

Palach also noted that the company believes combining operational flexibility with rigorous oversight of scientific data is beneficial.¹ This approach is thought to support the disciplined execution of the research strategy as various programs advance.¹ This strategic focus on advancing drug discovery programs is aimed at creating long-term value for the parent company.¹

MitoCareX Bio functions as a focused drug-discovery platform designed to generate potential therapeutic candidates.¹ The company's mission is to convert its multidisciplinary scientific capabilities into these potential new medicines.¹ To achieve this, MitoCareX integrates biology, chemistry, and research enabled by computational methods.¹ These integrated research activities are directed toward the identification and development of drug candidates.¹

Beyond its ownership of MitoCareX, Nexentis Technologies has a separate investment strategy focused on renewable energy assets in Europe.¹ For these energy investments, the company employs a business model described as "Ready to Build," or RTB.¹ Nexentis is currently the lead investor in four different solar projects.¹ These projects are spread across three countries within the European Union and were all introduced by Solterra Renewable Energy Ltd.¹ Solterra Renewable Energy Ltd. is identified as a wholly owned subsidiary of another company, Solterra Energy Ltd.¹

The press release from Nexentis specified that it includes forward-looking statements.¹ These projections fall under statutory safe harbor protections established by legislation passed in 1995 concerning private investor lawsuits and related federal legal rules.¹ Statements regarding the anticipated benefits of moving to Google Cloud Platform are considered forward-looking.¹ This classification also applies to expectations of improved computational capacity, data governance, and operational flexibility.¹ Any claims about the potential effect of these new capabilities on MitoCareX's research and drug discovery efforts are also forward-looking.¹

The company warned that a number of risks could cause actual outcomes to differ materially from the forward-looking statements.¹ Among the cited risks are market and other conditions, a history of losses, and the need for additional capital.¹ Uncertainties about cash flows and the company's ability to fund its working capital needs were also listed as potential issues.¹ Additional risks involve the initiation, timing, progress, and results of preclinical studies, clinical trials, and other development efforts for product candidates.¹ Nexentis noted that more information on these factors is available in its public reports filed with the SEC, including its Form 10-K filed on March 31, 2026.¹ The company stated that it has no obligation to publicly revise these forward-looking statements to reflect future events, unless required by law.¹